Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma?

被引:0
作者
Andrew Jacobs
机构
[1] Chief of Cancer Care Services and Medical Director of Clinical Research at the Benaroya Research Institute at Virginia Mason Medical Center,
来源
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:424 / 425
页数:1
相关论文
共 4 条
[1]  
Burris HA(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 2403-2413
[2]  
Berlin JD(2002)Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone with patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 3270-3275
[3]  
Rocha Lima CM(2004)Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776-3783
[4]  
Louvet C(2005)Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509-3516